Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with bone disease severity in Rett syndrome.


Journal

BMC medical genetics
ISSN: 1471-2350
Titre abrégé: BMC Med Genet
Pays: England
ID NLM: 100968552

Informations de publication

Date de publication:
31 01 2020
Historique:
received: 16 06 2019
accepted: 23 01 2020
entrez: 2 2 2020
pubmed: 2 2 2020
medline: 4 3 2020
Statut: epublish

Résumé

More than 95% of individuals with RTT have mutations in methyl-CpG-binding protein 2 (MECP2), whose protein product modulates gene transcription. The disorder is caused by mutations in a single gene and the disease severity in affected individuals can be quite variable. Specific MECP2 mutations may lead phenotypic variability and different degrees of disease severity. It is known that low bone mass is a frequent and early complication of subjects with Rett syndrome. As a consequence of the low bone mass Rett girls are at an increased risk of fragility fractures. This study aimed to investigate if specific MECP2 mutations may affects the degree of involvement of the bone status in Rett subjects. In 232 women with Rett syndrome (mean age 13.8 ± 8.3 yrs) we measured bone mineral density at whole body and at femur (BMD-FN and BMD-TH) by using a DXA machine (Hologic QDR 4500). QUS parameters were assessed at phalanxes by Bone Profiler-IGEA (amplitude dependent speed of sound: AD-SoS and bone transmission time: BTT). Moreover, ambulation capacity (independent or assisted), fracture history and presence of scoliosis were assessed. We divided the subjects with the most common point mutations in two group based on genotype-phenotype severity; in particular, there has been consensus in recognising that the mutations R106T, R168X, R255X, R270X are considered more severe. As aspect, BMD-WB, BMD-FN and BMD-TH were lower in subjects with Rett syndrome that present the most severe mutations with respect to subjects with Rett syndrome with less severe mutations, but the difference was statistically significant only for BMD-FN and BMD-TH (p < 0.05). Also both AD-SoS and BTT values were lower in subjects that present the most severe mutations with respect to less severe mutations but the difference was not statistically significant. Moreover, subjects with Rett syndrome with more severe mutations present a higher prevalence of scoliosis (p < 0.05) and of inability to walk (p < 0.05). This study confirms that MECP2 mutation type is a strong predictor of disease severity in subjects with Rett syndrome. In particular, the subjects with more severe mutation present a greater deterioration of bone status, and a higher prevalence of scoliosis and inability to walk.

Sections du résumé

BACKGROUND
More than 95% of individuals with RTT have mutations in methyl-CpG-binding protein 2 (MECP2), whose protein product modulates gene transcription. The disorder is caused by mutations in a single gene and the disease severity in affected individuals can be quite variable. Specific MECP2 mutations may lead phenotypic variability and different degrees of disease severity. It is known that low bone mass is a frequent and early complication of subjects with Rett syndrome. As a consequence of the low bone mass Rett girls are at an increased risk of fragility fractures. This study aimed to investigate if specific MECP2 mutations may affects the degree of involvement of the bone status in Rett subjects.
METHODS
In 232 women with Rett syndrome (mean age 13.8 ± 8.3 yrs) we measured bone mineral density at whole body and at femur (BMD-FN and BMD-TH) by using a DXA machine (Hologic QDR 4500). QUS parameters were assessed at phalanxes by Bone Profiler-IGEA (amplitude dependent speed of sound: AD-SoS and bone transmission time: BTT). Moreover, ambulation capacity (independent or assisted), fracture history and presence of scoliosis were assessed. We divided the subjects with the most common point mutations in two group based on genotype-phenotype severity; in particular, there has been consensus in recognising that the mutations R106T, R168X, R255X, R270X are considered more severe.
RESULTS
As aspect, BMD-WB, BMD-FN and BMD-TH were lower in subjects with Rett syndrome that present the most severe mutations with respect to subjects with Rett syndrome with less severe mutations, but the difference was statistically significant only for BMD-FN and BMD-TH (p < 0.05). Also both AD-SoS and BTT values were lower in subjects that present the most severe mutations with respect to less severe mutations but the difference was not statistically significant. Moreover, subjects with Rett syndrome with more severe mutations present a higher prevalence of scoliosis (p < 0.05) and of inability to walk (p < 0.05).
CONCLUSION
This study confirms that MECP2 mutation type is a strong predictor of disease severity in subjects with Rett syndrome. In particular, the subjects with more severe mutation present a greater deterioration of bone status, and a higher prevalence of scoliosis and inability to walk.

Identifiants

pubmed: 32005172
doi: 10.1186/s12881-020-0960-2
pii: 10.1186/s12881-020-0960-2
pmc: PMC6995101
doi:

Substances chimiques

MECP2 protein, human 0
Methyl-CpG-Binding Protein 2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

21

Références

Am J Med Genet A. 2004 Apr 15;126A(2):129-40
pubmed: 15057977
Ann Neurol. 2010 Dec;68(6):944-50
pubmed: 21154482
Bone. 2008 Apr;42(4):737-42
pubmed: 18242156
Pediatr Res. 2011 Apr;69(4):359-64
pubmed: 21178819
Neuron. 2007 Nov 8;56(3):422-37
pubmed: 17988628
Ment Retard Dev Disabil Res Rev. 2002;8(2):61-5
pubmed: 12112728
Pediatr Res. 2008 Oct;64(4):435-9
pubmed: 18535484
Bone. 2006 Jul;39(1):159-73
pubmed: 16473568
Bone. 2015 Feb;71:106-14
pubmed: 25445449
J Med Genet. 2003 May;40(5):e52
pubmed: 12746406
J Clin Endocrinol Metab. 2013 Dec;98(12):E1972-8
pubmed: 24106287
Bone. 2015 May;74:191-8
pubmed: 25659951
J Med Genet. 2014 Mar;51(3):152-8
pubmed: 24399845
Pediatr Res. 2019 Apr;85(5):639-643
pubmed: 30188498
Neurology. 2008 Apr 15;70(16):1313-21
pubmed: 18337588
Am J Med Genet. 2000 Summer;97(2):147-52
pubmed: 11180222
Eur J Hum Genet. 2005 Oct;13(10):1121-30
pubmed: 16077736
Bone. 2010 Sep;47(3):701-5
pubmed: 20601296
Pediatr Res. 2011 Apr;69(4):293-8
pubmed: 21178825
J Med Genet. 2004 Jan;41(1):25-30
pubmed: 14729826
Calcif Tissue Int. 2014 Sep;95(3):248-56
pubmed: 25012506
J Bone Miner Res. 2011 Sep;26(9):2280-6
pubmed: 21590733
Am J Med Genet A. 2012 Feb;158A(2):340-50
pubmed: 22190343
PLoS One. 2016 Feb 05;11(2):e0146824
pubmed: 26849438
Pediatr Res. 2010 Nov;68(5):446-51
pubmed: 20661168
Brain Dev. 1990;12(1):154-6
pubmed: 2344012
J Bone Miner Res. 2000 Aug;15(8):1603-14
pubmed: 10934660
Bone. 2012 Apr;50(4):830-5
pubmed: 22306927
Pediatr Neurol. 2017 May;70:20-25
pubmed: 28347601
J Child Neurol. 2006 Sep;21(9):809-13
pubmed: 16970893
Calcif Tissue Int. 2001 Nov;69(5):259-62
pubmed: 11768194
Bone. 2009 Aug;45(2):346-56
pubmed: 19414073
Pediatrics. 2008 Mar;121(3):540-6
pubmed: 18310203
Neurology. 2008 Mar 11;70(11):868-75
pubmed: 18332345

Auteurs

Carla Caffarelli (C)

Department of Medicine, Surgery and Neuroscience, University of Siena, Policlinico Le Scotte, Viale Bracci 2, 53100, Siena, Italy. carlacaffarelli@yahoo.it.

Stefano Gonnelli (S)

Department of Medicine, Surgery and Neuroscience, University of Siena, Policlinico Le Scotte, Viale Bracci 2, 53100, Siena, Italy.

Maria Dea Tomai Pitinca (MDT)

Department of Medicine, Surgery and Neuroscience, University of Siena, Policlinico Le Scotte, Viale Bracci 2, 53100, Siena, Italy.

Silvia Camarri (S)

Department of Medicine, Surgery and Neuroscience, University of Siena, Policlinico Le Scotte, Viale Bracci 2, 53100, Siena, Italy.

Antonella Al Refaie (A)

Department of Medicine, Surgery and Neuroscience, University of Siena, Policlinico Le Scotte, Viale Bracci 2, 53100, Siena, Italy.

Joussef Hayek (J)

Paediatrics Neuropsychiatry Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy.

Ranuccio Nuti (R)

Department of Medicine, Surgery and Neuroscience, University of Siena, Policlinico Le Scotte, Viale Bracci 2, 53100, Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH